ABCL AbCellera Biologics Inc.

NASDAQ
$11.43

AbCellera Biologics Inc. (ABCL) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.18 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +97.4% since its last earnings release on August 5, 2026.

AbCellera Biologics Missed Consensus Estimates
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.18)
Rev est $7.15M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.46

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.

Sector

Healthcare

Industry

Biotechnology